Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

CRA International Forecasts Revenue Increase for Fiscal Year 2024

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

The consulting firm CRA International is projecting a revenue increase for the fiscal year 2024, with expected earnings ranging from $645 million to $675 million. This forecast surpasses the previous estimate of $630.81 million, indicating potential growth and success for the company in the upcoming year.

CRA International, Inc. Stock Price Soars on February 29, 2024: Positive Momentum and Future Growth Potential

On February 29, 2024, CRA International, Inc. (CRAI) experienced a significant increase in its stock price, trading near the top of its 52-week range and above its 200-day simple moving average. According to data from CNN Money, the price of CRAI shares rose by $14.57 since the market last closed, representing a 12.35% increase. The stock opened at $119.50 on that day, which was $1.49 higher than its previous close. This strong opening price indicated positive momentum for CRAI, as investors showed confidence in the company’s performance and future prospects. CRA International, Inc. is a consulting firm that provides economic, financial, and management consulting services to businesses, government agencies, and law firms. The company’s strong performance on February 29th may have been driven by positive news, strong financial results, or favorable market conditions. Investors who held CRAI stock on that day would have seen a significant increase in the value of their investment. The stock’s price momentum and strong opening price suggest that CRAI may continue to perform well in the future, attracting more investors and potentially reaching new highs. Overall, CRA International, Inc.’s stock performance on February 29, 2024, was impressive, demonstrating the company’s strong position in the market and its potential for continued growth. Investors will be keeping a close eye on CRAI’s future performance to see if it can sustain this positive momentum.

CRAI Stock Performance Analysis: Total Revenue, Net Income, and EPS Show Mixed Results on February 29, 2024

On February 29, 2024, CRAI stock had a mixed performance based on the latest financial data provided by CNN Money. The company reported a total revenue of $590.90 million for the past year, which represented a 4.41% increase compared to the previous year. However, the total revenue for the third quarter of the year was $147.55 million, showing a decrease of 8.9% compared to the previous quarter. CRAI also reported a net income of $43.45 million for the past year, reflecting a 4.69% increase compared to the previous year. However, the net income for the third quarter of the year was $8.57 million, indicating a decrease of 9.57% compared to the previous quarter. In terms of earnings per share (EPS), CRAI reported $5.91 for the past year, showing an increase of 8.48% compared to the previous year. However, the EPS for the third quarter of the year was $1.21, reflecting a decrease of 9.61% compared to the previous quarter. Overall, CRAI stock had a mixed performance on February 29, 2024, with increases in total revenue, net income, and EPS compared to the previous year, but decreases in these metrics compared to the previous quarter. Investors and analysts may need to closely monitor the company’s financial performance in the coming quarters to assess its future growth potential and stock performance.

Tags: CRAI
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Financial plannings

Financial Advisor Tech: Exploring the Latest Integration Trends Shaping Advisor-Custodial Technology

Finance analyst

Great Elm Capital Reports Strong FourthQuarter Sales Growth

TriMas Projects LowerthanExpected Financial Performance for FY2024

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com